Gilead Sciences, Inc. (GILD) - Deep Dive Research Report

Prepared 2026-06-17. Listing venue: Nasdaq (GILD). Sector: Healthcare / Biopharmaceuticals.

Six earnings calls used in this report:

1. Q1 2026 - May 7, 2026 (most recent; within 90 days of report date)
2. Q4 / Full-Year 2025 - February 10, 2026
3. Q3 2025 - October 30, 2025
4. Q2 2025 - August 7, 2025
5. Q1 2025 - April 24, 2025
6. Q4 / Full-Year 2024 - February 11, 2025

Section 1: What the Company Does

Gilead Sciences makes medicines that fight viruses, and increasingly, cancer and liver disease. Its single most important fact is this: roughly seven of every ten dollars Gilead earns comes from HIV. If you are one of the tens of millions of people worldwide living with HIV, or at risk of acquiring it, there is a very good chance the pill you take every morning - or, increasingly, the shot you get twice a year - was made by Gilead.

The company was founded in 1987 in Foster City, California, by Michael Riordan, a 29-year-old physician who had survived dengue fever and became obsessed with antiviral drugs at a time when the field barely existed. The name comes from the "balm of Gilead," a healing ointment referenced in the Bible. For its first 15 years Gilead was a science project in search of a blockbuster. The turning point was its mastery of nucleotide chemistry - the ability to design molecules that mimic the building blocks of DNA and RNA and jam the machinery a virus uses to copy itself. That chemistry produced tenofovir, the backbone of nearly every HIV regimen Gilead has sold for two decades.

The core value proposition is brutally simple and extraordinarily durable. HIV is not curable, but it is controllable: a person who takes the right daily pill can drive the virus to undetectable levels, live a normal lifespan, and - critically - cannot transmit it to others ("U=U", undetectable equals untransmittable). Gilead built the best, safest, most convenient pills to do that. Biktarvy, a single tablet combining three drugs (bictegravir, emtricitabine, tenofovir alafenamide), is taken by more than half of all newly treated and switching HIV patients in the United States. Once a patient is stable on a regimen that works and has no side effects, neither they nor their doctor has any reason to switch. That is the engine.

What makes this hard to replicate is the combination of (1) decades of accumulated chemistry and clinical-trial data proving safety in a population that takes the drug for life, (2) a fully built global commercial and government-contracting apparatus (HIV is heavily funded by public payers and programs like the US Ryan White program and PEPFAR), and (3) a patent and formulation moat where Gilead keeps inventing the next longer-acting version before the current one goes generic.

A concrete example of Gilead's product in action is its newest one. In June 2025 the FDA approved Yeztugo (lenacapavir), the first and only HIV prevention medicine given as an injection just twice a year. A person at risk of HIV walks into a clinic, gets a shot, and is protected for six months - no daily pill to remember. In the pivotal trials, the rate of new infections was effectively zero. This is the kind of step-change Gilead has spent 35 years building the capability to deliver: take a chronic-disease franchise built on daily pills and convert it into something you barely have to think about.

"We fully expect to see our leadership in HIV continue and extend beyond the 2030s based on our long-acting portfolio." - Daniel O'Day, Chairman & CEO (Q4 2024 call, Feb 11 2025)

The newer chapters of Gilead - oncology and liver disease - were bought, not built, and are covered in detail below.

Section 2: Business Segments

Gilead reports financially as a single operating segment, but it manages the business as four distinct commercial franchises with very different products, competitors, and economics. They are treated here as segments because that is how management runs and discusses them.

2.1 HIV (the engine - roughly 72% of product sales)

This is the business. Full-year 2025 HIV sales were $20.8 billion, up 6%, a record (Q4 2025 call). It rests on Biktarvy ($14.3 billion in 2025, +7%, with over 52% US treatment market share), the daily single-tablet regimen that is the default choice for treating HIV in the developed world, and Descovy ($2.8 billion, +31%), a two-drug backbone used both in treatment and as a daily PrEP (pre-exposure prophylaxis) pill to prevent HIV.

The core capability is twofold. First, tenofovir alafenamide (TAF) chemistry - a refined version of Gilead's original tenofovir that delivers the drug more efficiently, allowing lower doses and better kidney and bone safety. Second, an unmatched library of long-term safety data: doctors prescribe Biktarvy because Gilead can show what happens to patients over many years, which a new entrant cannot. The segment exists as the historical core of the company and is the cash cow that funds everything else.

The strategic story now is the pivot from daily pills to long-acting medicines, where the segment is also the growth bet. Yeztugo (lenacapavir for prevention), twice-yearly, launched mid-2025 and is being guided to $1 billion in its first full year (Q1 2026 call, raised from $800 million). The next prize is a once-daily oral and eventually less-frequent bictegravir + lenacapavir treatment regimen (the ARTISTRY trial program), targeted to launch in early 2027 (Q3 2025 call) - the move designed to defend the Biktarvy franchise against patent expiry by giving patients an even better next-generation option to switch into.

2.2 Liver Disease (roughly 11% of product sales)

Full-year 2025 liver sales were about $3.2 billion, up 6% (Q4 2025 call). This franchise has two halves. The legacy half is hepatitis C - Epclusa, Harvoni, Vosevi, Sovaldi - the drugs that actually cure HCV. These came from Gilead's 2011 acquisition of Pharmasset and made the company tens of billions of dollars; but a cure shrinks its own market, so HCV is in managed decline. The other legacy product is Vemlidy for hepatitis B (chronic, not curable, so steadier).

The growth driver is Livdelzi (seladelpar), acquired through the 2024 purchase of CymaBay for roughly $4.3 billion. Livdelzi treats primary biliary cholangitis (PBC), an autoimmune liver disease. It launched in late 2024, generated about $30 million in its first full quarter (Q4 2024 call), and by Q1 2026 had more than tripled year-over-year to $133 million with over 50% market share, helped by a competitor's withdrawal (Q1 2026 call). The segment's core capability is Gilead's deep liver-disease (hepatology) commercial relationships built over the HCV years, which it is now reusing to sell Livdelzi. A coming addition is bulevirtide (Hepcludex) for hepatitis D, already sold in Europe, with a US decision expected in 2026.

2.3 Oncology - Trodelvy and Cell Therapy (roughly 12% of product sales)

Oncology is the expensive, hard-fought diversification bet. It has two parts.

Trodelvy (sacituzumab govitecan) is an antibody-drug conjugate (ADC) - an antibody that homes in on the TROP-2 protein on tumor cells and delivers a chemotherapy payload directly to them. It came from the 2020 acquisition of Immunomedics for about $21 billion. Trodelvy is the established standard in second-line metastatic triple-negative breast cancer (TNBC), grew 37% year-over-year to $402 million in Q1 2026 (Q1 2026 call), and is pushing into first-line TNBC and other tumor types. Its core capability is being one of the few proven, approved TROP-2 ADCs on the market.

Cell Therapy - Yescarta and Tecartus - are CAR-T therapies from the 2017 acquisition of Kite Pharma for about $11.9 billion. These are living drugs: a patient's own T-cells are extracted, genetically reengineered to hunt their cancer, and reinfused. The capability here is a fearsomely complex manufacturing and logistics chain (every dose is bespoke to one patient). This sub-franchise is shrinking - down 7% in 2025 with a further ~10% decline guided for 2026 (Q4 2025 call) - as competition in lymphoma intensifies. Gilead is trying to revitalize cell therapy through its 2026 acquisition of Arcellx ($7.8 billion, closed April 28 2026) and its lead asset anito-cel, a CAR-T for multiple myeloma with a PDUFA (FDA decision) date in December 2026 (Q1 2026 call).

2.4 Veklury (remdesivir) - the COVID tail (low single-digit % and falling)

Veklury is the antiviral remdesivir, used in hospitals for COVID-19. It was a multi-billion-dollar product at the pandemic peak and is now a declining, lumpy revenue tail tied to COVID hospitalization waves. Management strips it out and reports a "base business excluding Veklury" number precisely because it is no longer a strategic driver. It is included here for completeness, not because it shapes the thesis.

Segment summary

Section 3: Products and Business Detail

The HIV portfolio. Biktarvy is the flagship: one pill, once daily, three active ingredients, the most-prescribed HIV regimen in the US. Descovy (two-drug, emtricitabine + TAF) serves both as a treatment backbone and as a daily prevention (PrEP) pill; its PrEP use drove 38% growth to $807 million in Q1 2026 and US PrEP demand up 87% year-over-year (Q1 2026 call). Truvada and Genvoya/Odefsey/Stribild are older regimens now facing or past generic competition. Sunlenca is lenacapavir for treatment of heavily treatment-experienced patients with multidrug-resistant HIV. Yeztugo is the same molecule, lenacapavir, formulated and approved for twice-yearly preventive injection - the marquee launch.

Lenacapavir is worth a technical aside because it is the foundation of Gilead's next decade. It is a first-in-class capsid inhibitor: it interferes with the protein shell (capsid) the virus needs at multiple stages of its life cycle. Because it works at picomolar potency and has a very long half-life, it can be dosed every six months by injection - the property that makes twice-yearly prevention possible. In the PURPOSE-1 and PURPOSE-2 trials, lenacapavir for PrEP showed near-total prevention of new infections, results good enough that the World Health Organization issued guidelines recommending it (Q2 2025 call).

The liver portfolio. Epclusa (sofosbuvir/velpatasvir) and Vosevi cure most genotypes of hepatitis C in 8-12 weeks; Harvoni and Sovaldi are the earlier-generation cures. Vemlidy (TAF) suppresses hepatitis B. Livdelzi (seladelpar) is a once-daily oral for PBC that improves liver biochemistry markers and itch. Hepcludex (bulevirtide) treats hepatitis D in Europe.

The oncology portfolio. Trodelvy (TROP-2 ADC) for metastatic TNBC and urothelial cancer, expanding toward first-line breast and lung indications. Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel) are CD19-directed CAR-T therapies for large B-cell lymphoma and mantle-cell lymphoma. Coming: anito-cel (anitocel, BCMA-directed CAR-T for multiple myeloma, from Arcellx) and ADC assets from the 2026 Tubulis acquisition (lead asset TUB-040 for ovarian and lung cancer, described by CMO Dietmar Berger as having "unprecedented data," Q1 2026 call).

Manufacturing and delivery. Small-molecule pills (the HIV and liver portfolios) are produced through conventional but tightly regulated pharmaceutical chemical synthesis and formulation, with Gilead managing a global supply chain and a network of contract manufacturers. The biologics are harder: Trodelvy is an ADC requiring antibody production plus chemical conjugation of the toxic payload under exacting controls. CAR-T (Yescarta, Tecartus, and the coming anito-cel) is the most complex - an individualized cell-manufacturing process where a patient's cells are shipped to a Gilead/Kite facility, engineered, quality-tested, and returned, with a turnaround time measured in days and zero tolerance for contamination. This logistics complexity is itself a barrier and a constraint on cell-therapy growth.

Geographies and access. The treatment business is concentrated in the United States and other developed markets where reimbursement supports premium pricing. But HIV is uniquely global, and Gilead runs a large access operation: it has agreed with the Global Fund and the US State Department (through PEPFAR) to supply enough lenacapavir for PrEP to reach up to 2 million people over three years in low- and lower-middle-income countries (Q3 2025 call), and licenses generic manufacturers for low-income markets. In Europe, lenacapavir for PrEP is approved under the name Yeytuo (EU approval, August 2025).

Milestones that reshaped the company. Pharmasset (2011, ~$11B) created the HCV cure franchise. Kite (2017, ~$11.9B) bought into CAR-T. Immunomedics (2020, ~$21B) bought Trodelvy. CymaBay (2024, ~$4.3B) bought Livdelzi. And in a 60-day burst in early 2026, Gilead acquired Arcellx ($7.8B), Tubulis, and Ouro Medicines, generating a combined acquired-in-process-R&D (IPR&D) charge of $11.5 billion that pushes 2026 GAAP results to a loss (Q1 2026 call; Bloomberg, May 7 2026).

Section 4: Customers

Gilead does not sell to patients directly. Its customers sit in a layered chain: wholesalers and specialty distributors that take physical product, the prescribing physicians who choose the drug, and the payers (insurers and government programs) that actually fund it. Understanding who holds the power at each layer explains the durability of the business.

Who prescribes. For HIV, the buyer is a relatively concentrated community of infectious-disease and HIV-specialist physicians plus, increasingly for PrEP, primary-care and sexual-health clinicians. Management noted that most early Yeztugo prescribers are existing HIV PrEP clinicians (Q3 2025 call). For oncology and cell therapy, the prescriber is an oncologist or a specialized cancer-center team. For liver, it is hepatologists and gastroenterologists - the same audience Gilead cultivated during the HCV years and is now reusing for Livdelzi.

Who pays. This is the crucial point for revenue predictability. HIV in the US is funded heavily by government and quasi-government channels: Medicaid, Medicare Part D, the Ryan White program, and the 340B drug-pricing program, plus commercial insurance. This makes the business unusually exposed to government policy (see Section 8) but also unusually sticky, because formulary placement and payer coverage are slow to change. Management cited achieving "90% coverage well ahead of our one-year target" for Yeztugo (Q4 2025 call) - payer access is the gating metric they manage to.

Why they choose Gilead. For physicians, the reasons are specific: Biktarvy has the deepest long-term safety record, the fewest drug interactions, no requirement for baseline resistance testing in many cases, and a single-tablet convenience. For PrEP, Yeztugo's twice-yearly dosing solves the adherence problem that undermines daily pills - a person who forgets pills is protected by a shot. These are clinical, not price, reasons, which is why Gilead commands premium positioning.

Switching costs. Extremely high at the patient level, lower at the franchise level. An individual patient stable on an effective, well-tolerated regimen almost never switches - the downside (viral rebound, resistance) is catastrophic and the upside negligible. That creates an installed base that generates revenue for years. The franchise-level risk is at the new-start and patent-cliff margin: when Biktarvy's patents lapse, generics will compete for new patients, which is exactly why Gilead is racing to launch the lenacapavir-based next generation before that happens.

Concentration and contracts. Customer concentration is at the distributor level (a handful of large wholesalers handle most US volume) rather than the demand level, which is diffuse across hundreds of thousands of patients - a healthy structure. Contracting is a mix of wholesaler agreements, payer rebate contracts, and government pricing schemes. Revenue is recurring and chronic by nature (patients refill for life), giving high visibility, partially offset by the policy-driven gross-to-net pressures discussed below.

Section 5: Competitive Landscape

Gilead competes in three quite different arenas, and its position is strongest where it has spent the longest.

HIV - dominant but contested at the long-acting frontier. Gilead's only serious HIV rival is ViiV Healthcare, the joint venture majority-owned by GSK with Pfizer and Shionogi as minority holders. ViiV holds roughly 30% of the global antiretroviral market and is the innovator in long-acting injectable treatment: its Cabenuva (cabotegravir + rilpivirine) is dosed monthly or every two months, and its Apretude (cabotegravir) was the first long-acting injectable for PrEP, dosed every two months. The strategic battle is now long-acting versus long-acting: ViiV is ahead in injectable treatment today, while Gilead's twice-yearly Yeztugo leapfrogs Apretude's every-two-months cadence in prevention. Merck is the other entrant, with the NNRTI doravirine and its own oral and long-acting candidates aimed at treatment-naive patients. Gilead wins on its installed base, single-tablet convenience, and the six-month dosing of lenacapavir; it is most exposed if ViiV or Merck deliver a clearly superior long-acting treatment before Gilead's bictegravir-lenacapavir regimen arrives in 2027.

Oncology - a follower, not a leader. In ADCs, Gilead's Trodelvy competes most directly with AstraZeneca/Daiichi Sankyo's Enhertu and the broader Datroway (datopotamab, also a TROP-2 ADC) program, which is a direct threat to Trodelvy's franchise. In CAR-T, Yescarta and Tecartus compete with Bristol Myers Squibb (Breyanzi, Abecma) and Novartis (Kymriah); in the multiple-myeloma CAR-T race that anito-cel is entering, the incumbents are BMS's Abecma and Johnson & Johnson/Legend's Carvykti. Gilead is a credible but not dominant oncology player and is buying its way to relevance.

Liver - structurally favorable. In HCV, AbbVie's Mavyret is the main competitor, but the whole category shrinks as patients are cured. In PBC, Livdelzi's main rival had been Intercept's Ocaliva and Ipsen's Iqirvo; Gilead benefited from a competitor withdrawal, which helped Livdelzi take over 50% share (Q1 2026 call).

Barriers to entry. High in HIV (decades of safety data, patents, government-contracting scale, prescriber inertia), high in cell therapy (manufacturing complexity), moderate in ADCs and small-molecule liver drugs. The structural risk to Gilead is not a new entrant from scratch but the patent cliff converting its own moat into a generic free-for-all on legacy products.

Market caps are approximate peer-size references only, dated June 2026; they move daily and are not used for any valuation of Gilead.

Section 6: Industry

What drives demand. Gilead's demand is driven by chronic-disease prevalence and the slow expansion of treatment and prevention. HIV is the structural core: roughly 39 million people live with HIV worldwide, about 1.2 million in the US, and roughly 1.3 million new infections occur globally each year. Treatment demand is near-permanent (lifelong therapy), while prevention (PrEP) is the genuine growth vector - only a fraction of the people who would benefit from PrEP currently take it, and a twice-yearly shot dramatically widens the addressable pool. Oncology demand is driven by rising cancer incidence and the shift toward targeted biologics; liver demand by the diagnosed pools of PBC, HBV, and HDV patients.

Industry size and growth. The global HIV drugs market was about $38 billion in 2025 and is projected to grow to roughly $40-47 billion by the early 2030s at a mid-single-digit CAGR (Transparency Market Research; Fortune Business Insights). Gilead is the largest single player in it. The broader oncology and ADC markets are growing faster (double-digit) but are far more crowded.

Where Gilead sits in the supply chain. Gilead is an originator/innovator - it discovers or acquires the molecule, runs the trials, owns the patents, manufactures (directly and via contractors), and sells through distributors. It is at the top of the value chain, capturing the innovation premium, with generic manufacturers waiting downstream for patents to expire.

Regulatory environment. This is a heavily regulated industry where the FDA (and EMA, etc.) approval is the gate to every dollar of revenue, and where pricing is shaped by government policy. The two policy forces that matter most to Gilead today are (1) the Inflation Reduction Act's Medicare Part D redesign, which shifted more drug cost onto manufacturers and created an explicit ~$1.1 billion revenue headwind in 2025 (about $900 million of it in HIV) (Q4 2024 call), and (2) the IRA's Medicare price-negotiation mechanism, which could eventually touch high-spend HIV products. The 340B program and PEPFAR funding levels also swing volumes and economics.

Cyclicality. Low. Demand for HIV and chronic-disease medicines is largely recession-proof - patients do not stop taking life-sustaining drugs in a downturn. The cyclicality Gilead has is policy-driven and patent-driven, not macro-driven. Veklury added pandemic-linked lumpiness, now fading.

Tailwinds: expanding global PrEP access, the long-acting injectable shift, growing oncology/ADC markets, and aging populations. Headwinds: drug-pricing politics (IRA, potential tariffs on pharma imports, most-favored-nation pricing proposals), patent expiries on legacy HIV products, and the secular shrinkage of the HCV cure market.

Section 7: Growth Triggers

All triggers below are drawn directly from the six earnings calls and cited to the call.

• Yeztugo (lenacapavir for PrEP) scaling to blockbuster in its first full year. 2026 guidance raised to $1 billion, up from the $800 million given a quarter earlier. (Q1 2026 call, May 7 2026 - raised from Q4 2025 call, Feb 10 2026)

"We are increasing our 2026 Yeztugo guidance to $1 billion, potentially achieving blockbuster status in its first full year." - Johanna Mercier (Q1 2026 call)

• Bictegravir + lenacapavir long-acting treatment regimen, targeted launch early 2027. The ARTISTRY-1 and ARTISTRY-2 Phase III programs are evaluating this next-generation regimen designed to extend HIV leadership past the Biktarvy patent cliff. (Q3 2025 call, Oct 30 2025)

• Anito-cel (Arcellx CAR-T for multiple myeloma), FDA PDUFA decision December 2026. Described as a potential "one-and-done treatment with stellar efficacy without compromising on safety." (Q1 2026 call, May 7 2026)

• Trodelvy expansion into first-line metastatic TNBC and beyond. Now NCCN-recommended in first- and second-line metastatic TNBC; growing 37% year-over-year. (Q4 2025 call, Feb 10 2026; Q1 2026 call)

• Bulevirtide (Hepcludex) US regulatory decision for hepatitis D, expected in 2026. (Q1 2026 call, May 7 2026)

• Tubulis ADC platform (lead asset TUB-040 for ovarian/lung cancer). Described as "transformational" with "unprecedented data." (Q1 2026 call, May 7 2026)

• Livdelzi (seladelpar) continued share capture in PBC. More than tripled year-over-year with over 50% market share following a competitor withdrawal. (Q1 2026 call, May 7 2026)

• A pipeline cadence of up to four additional product launches and five Phase III readouts targeted across 2026. Named launches across the calls include Trodelvy first-line TNBC, the bictegravir-lenacapavir HIV regimen, anito-cel, and bulevirtide. (Q4 2025 call, Feb 10 2026; Q1 2026 call)

• Global PrEP access agreement to reach up to 2 million people over three years via the Global Fund and PEPFAR in low- and lower-middle-income countries - a volume (not high-margin) driver that expands the franchise footprint. (Q3 2025 call, Oct 30 2025)

Section 8: Key Risks

1. The Biktarvy patent cliff (high probability, high impact). Biktarvy is roughly half of all Gilead product sales. Its core patents begin to lapse toward the end of this decade, after which generics can compete for new-start patients and erode the franchise. The mechanism is mechanical: even with a sticky installed base, generic competition collapses price and new-patient capture. Gilead's entire long-acting strategy (lenacapavir, the bictegravir-lenacapavir regimen) is fundamentally a defense against this. If the next-generation regimen slips or underperforms, the cliff arrives without a bridge.

2. US drug-pricing policy (high probability, moderate-to-high impact). The IRA Medicare Part D redesign already cost about $1.1 billion of 2025 revenue (~$900 million in HIV) (Q4 2024 call). Future Medicare price negotiation, 340B changes, "most-favored-nation" pricing proposals, or pharma tariffs could compound this. Because HIV is so heavily government-funded, Gilead is more exposed to US health policy than a typical biopharma.

3. The $16 billion 2026 acquisition spree may not pay off (moderate probability, high impact). In 60 days Gilead committed roughly $16 billion (Arcellx, Tubulis, Ouro) and booked an $11.5 billion IPR&D charge that turns 2026 GAAP results to a loss (Q1 2026 call; Bloomberg). These are early-stage, risky assets - anito-cel still needs FDA approval (Dec 2026) and must win a crowded myeloma CAR-T market. Gilead's M&A record is mixed: the Immunomedics ($21B) and Kite ($11.9B) deals have underdelivered relative to price. The mechanism of harm is straightforward - large goodwill/IPR&D write-offs and a cell-therapy business that is already shrinking 10% a year.

4. Cell-therapy decline (high probability, moderate impact). Yescarta/Tecartus fell 7% in 2025 with ~10% guided decline in 2026 (Q4 2025 call) as lymphoma competition intensifies. This is the part of the diversification thesis that is visibly not working, and anito-cel has to more than replace it.

5. Oncology ADC competition (moderate probability, moderate impact). Trodelvy faces a direct TROP-2 ADC threat from AstraZeneca/Daiichi's Datroway. If a rival ADC posts better data in the same indications, Trodelvy's growth runway narrows just as Gilead leans on it.

6. Concentration on a single therapeutic area (structural). Roughly 72% of sales is HIV. Any shock to that franchise - clinical, competitive, or regulatory - hits the whole company. Management's repeated emphasis on extending HIV "beyond the 2030s" is also an admission of how much rides on it.

Section 9: Walk the Talk

The six calls span February 2025 (Q4 2024) to May 2026 (Q1 2026). Across them, Gilead's management - led by CEO Daniel O'Day and CFO Andrew Dickinson - has been notably accurate on the things it controls (commercial execution, guidance), and appropriately cautious on policy headwinds it flagged early. The credibility weak spot is the long-running, capital-intensive oncology diversification.

HIV guidance: consistently met or beaten. In Q4 2024 (Feb 2025), management guided 2025 HIV growth that, absent the ~$1.1 billion policy headwind they explicitly named, would be 5-6%. By Q4 2025 (Feb 2026) HIV had grown 6% to a record $20.8 billion, with Biktarvy holding the >52% share they had promised to defend. They guided 2024 HIV to grow 5% and it grew 8% (Q4 2024 call). The pattern is conservative guidance, delivery at or above it.

"We have achieved our goal of 90% coverage well ahead of our one-year target." - management on Yeztugo payer access (Q4 2025 call)

This is a clean kept promise: in Q4 2024 they targeted ~75% US payer access within six months of the mid-2025 Yeztugo launch; by Q3 2025 they reported hitting 75% coverage "nearly three months ahead" of target, and by Q4 2025 reported 90%.

Yeztugo guidance: raised, not missed. The most recent and clearest credibility data point. Q4 2025 guided Yeztugo to $800 million in 2026; one quarter later (Q1 2026) they raised it to $1 billion on the back of Q1 sales of $166 million (+72% sequentially). Raising a launch-year guide a quarter in is the opposite of overpromising.

Livdelzi: under-promised, over-delivered. Q4 2024 described Livdelzi's first full quarter (~$30 million) as "exceeding internal expectations." By Q1 2026 it had more than tripled year-over-year to $133 million with >50% share. Kept and exceeded.

The honest disclosure on cell therapy. Management did not hide the weak spot. They guided cell therapy down ~10% for 2026 after a 7% decline in 2025 (Q4 2025 call) - a candid admission rather than a quietly dropped target. This honesty is itself a credibility marker, but it also confirms that a large, expensive acquisition (Kite) has not delivered durable growth.

The 2026 M&A pivot is the open question. The clearest test of management's word is still ahead. They have committed ~$16 billion and absorbed an $11.5 billion charge on the promise that anito-cel, Tubulis ADCs, and Ouro assets revitalize oncology and immunology. None of that has yet shown up in results; anito-cel's FDA decision is December 2026. Given the mixed payoff from Immunomedics and Kite, the market is right to withhold judgment - and notably, the stock fell sharply on the Q1 2026 print despite a raised sales guide, precisely because investors are skeptical of the acquisition strategy (TIKR, May 2026).

Assessment: On commercial execution and guidance, this is management that does what it says - usually conservatively guided and delivered. The credibility risk is not honesty; it is capital allocation. Gilead has repeatedly told a convincing HIV story and delivered it, while spending tens of billions on an oncology diversification that has yet to clearly justify its price. They walk the talk on the core business; the jury is out on the deals.

Section 10: Shareholder Friendliness Index

Dividends. Gilead has raised its dividend for over a decade and continued through this window. The quarterly dividend went from $0.77 in 2024 to $0.79 in 2025 (a 2.6% increase announced February 2025, Q4 2024 call) to $0.82 in 2026 (a 3.8% increase, announced with the Q1 2026 dividend declaration; gilead.com). That equates to annual DPS of roughly $3.08 (2024), $3.16 (2025), and $3.28 (2026 run-rate) - steady low-single-digit growth, no cuts, no specials. The dividend is well-covered by underlying (non-GAAP) earnings; the 2026 GAAP loss is driven entirely by the one-time $11.5 billion acquisition IPR&D charge and does not threaten the dividend, which is paid from cash flow.

Buybacks and dilution. Buybacks are real but secondary to dividends and M&A. For the trailing ~90 days, the MoatMap database records zero open-market buyback filings (a 90-day window only, not a three-year history). Looking back further from filings and the calls: Gilead repurchased about $1.9 billion of stock in full-year 2025, and returned $5.9 billion total to shareholders that year (about 63% of free cash flow) (Q4 2025 call); in Q1 2026 it repurchased $400 million+ as part of $1.4 billion returned (Q1 2026 call). Repurchases in 2024 were more modest as the CymaBay deal absorbed cash. Net shares outstanding have stayed roughly flat (around 1.24-1.25 billion) over the three years - buybacks have offset option dilution rather than meaningfully shrinking the count, because management has prioritized dividends and a heavy M&A program over aggressive retirement of shares.

Verdict: Returns Capital - a reliable, steadily growing dividend funded by strong cash flow is the primary channel, with buybacks used opportunistically and net share count held roughly flat; the bigger capital story is the multi-billion-dollar acquisition program, which competes with buybacks for cash.

Section 11: Insider Activities

Source: SEC Form 4 filings (US venue), via the MoatMap multiverse database (data current 2026-06-17 09:01 UTC) as the spine, with the most recent two weeks cross-checked against EDGAR. The block is not flagged stale.

The 12-month picture is unambiguous: no open-market purchases by any insider, and a steady stream of sales by senior executives. This is, however, the textbook pattern of executives at a large, mature pharma converting equity compensation - it is noise, not a bearish signal, and the absence of buying is normal for a company of this maturity (insiders here are paid largely in stock and routinely sell).

Recent transactions (most recent first):

Buys - the signal: there were zero open-market purchases by any director or officer in the trailing 12 months. There is therefore no bullish insider-buying signal to read. Cluster buying - the strongest signal in this section - is entirely absent.

Sells - the why: the selling is almost entirely explainable as routine, pre-planned, and compensation-driven. The recurring, identical 3,000-share monthly sales by CFO Dickinson and CCO Mercier on the 15th-16th of each month are the fingerprint of a scheduled 10b5-1 trading plan filed in advance, not opportunistic selling. The June 10 and March 10 "Other" transactions are the vesting of restricted/performance stock units with same-day share withholding to cover taxes (the priced sub-lines at a single uniform price on a single day). Mercier's May 15 activity pairs a 25,000-share option exercise at $66.64 (a long-dated, in-the-money option being monetized) with sales at market - again routine. CEO O'Day's larger one-off sales (10,000 in March, 15,000 in June) are consistent with diversification by a long-tenured executive and, on the dates shown, are most likely also 10b5-1-governed, though the specific plan footnote is not reproduced in the database. The April 30 director rows at $0 are the annual board equity retainer grant, not sales.

Net assessment: Insiders are net sellers, but the activity is broad-based, routine, plan-driven, and dominated by compensation mechanics rather than discretionary conviction selling. There is no acceleration, no clustered dumping, and no founder/PE exit. The one genuine information gap is the absence of any open-market buying - but for a mature large-cap pharma where executives are paid in equity, that absence is normal and not itself a warning. Read: neutral. Nothing here is a red flag; nothing here is bullish.

Section 12: Scenarios

Bull case. Gilead pulls off the long-acting transition cleanly. Yeztugo blows past its $1 billion first-full-year guide as twice-yearly prevention reshapes the PrEP market and pulls in people who never adhered to daily pills, and the global access deals expand the franchise's footprint without cannibalizing premium markets. The bictegravir-lenacapavir treatment regimen launches on time in early 2027, giving the millions of Biktarvy patients a clearly better next-generation option to switch into - so when Biktarvy's patents lapse, the franchise migrates to a fresh, patent-protected long-acting product instead of bleeding to generics. Meanwhile the 2026 acquisition spree starts to pay: anito-cel wins FDA approval in December 2026, takes share in multiple myeloma, and revives a cell-therapy business everyone had written off; Trodelvy holds first-line TNBC and the Tubulis ADCs read out well. Gilead exits the decade as a diversified company that still owns HIV but is no longer hostage to it, throwing off enough cash to keep raising the dividend.

Base case. The HIV engine keeps doing what it has done for years - mid-single-digit growth, Biktarvy holding share, Yeztugo scaling to and modestly past its guide. Livdelzi keeps gaining in PBC. Policy headwinds (Medicare Part D, possible negotiation) shave a predictable amount off the top each year, as they have, and management guides conservatively around them and delivers. The 2026 acquisitions are a wash: anito-cel gets approved but the myeloma CAR-T market is crowded, cell therapy stabilizes rather than reaccelerates, and the $11.5 billion charge is a one-time GAAP scar that does not touch the dividend. The company remains a steady, HIV-anchored cash compounder returning most of its free cash flow to shareholders, with the long-acting transition reducing but not eliminating the looming patent-cliff anxiety. Roughly what management has guided, nothing breaks, nothing dazzles.

Bear case. The transition stumbles where it matters most. The bictegravir-lenacapavir regimen slips past early 2027 or disappoints in trials, and ViiV or Merck land a clearly superior long-acting treatment first - so as Biktarvy's patents lapse, a huge chunk of Gilead's revenue migrates to generics and competitors instead of to Gilead's own next product. Yeztugo growth disappoints because payer access tightens or daily-pill habits prove stickier than hoped. Simultaneously, the expensive 2026 bets go wrong: anito-cel underwhelms or is delayed, cell therapy keeps shrinking, Trodelvy loses ground to AstraZeneca/Daiichi's competing TROP-2 ADC, and the $16 billion deployed becomes another set of write-downs in the lineage of Immunomedics and Kite. Layer on harsher US drug pricing - Medicare negotiation reaching HIV, tariffs, or most-favored-nation pricing - and a company that is ~72% one therapeutic area faces a concentrated, policy-amplified decline with no diversified growth to offset it. The dividend survives but growth evaporates.

Sources

• Gilead Q1 2026 earnings transcript - Motley Fool
• Gilead Q1 2026 financial results - Gilead.com
• Gilead forecasts 2026 loss on $11.5B acquisition charges - Bloomberg
• Gilead deploys $16B in 60 days - TIKR
• Gilead Q4/FY2025 earnings transcript - Motley Fool
• Gilead Q3 2025 earnings transcript - Motley Fool
• Gilead Q2 2025 earnings transcript - Motley Fool
• Gilead Q1 2025 earnings call - Gilead IR
• Gilead Q4 2024 earnings transcript - Motley Fool
• Gilead 3.8% Q1 2026 dividend increase - Gilead.com
• Gilead dividend history - StockAnalysis
• HIV drugs market size - Fortune Business Insights
• HIV drugs market outlook - Transparency Market Research
• AbbVie market cap - CompaniesMarketCap
• Bristol Myers Squibb market cap - CompaniesMarketCap
• GILD Q1 2026 Form 10-Q - SEC EDGAR

A note on what I could and could not verify: all six earnings calls were located and used (the most recent, Q1 2026, is within 90 days of today). Segment percentages are approximate, derived from the franchise sales figures management disclosed on the calls. Buyback figures older than 90 days come from the calls rather than line-item filings, and are stated with their windows. The independent analyst sources (SemiAnalysis, Stratechery, MBI Deep Dives) returned no Gilead coverage, so Section 13 is intentionally omitted.